Rhythm Pharmaceuticals (RYTM) PT Raised to $157 at Goldman Sachs
Tweet Send to a Friend
Goldman Sachs analyst Corinne Jenkins raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $157.00 (from $138.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
